Skip to content

Role of certain oral drug, nasal drops and leech therapy in migraine.

A randomised clinical trial on comparative efficacy of Nripvallabha Ghrita Nasya and Jalaukavacharana along with Pathyadi Ghana Vati orally in the management of Ardhavabhedaka w. s. r. to Migraine.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/07/020001
Enrollment
60
Registered
2019-07-02
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G439- Migraine, unspecified

Interventions

Intervention1: Nasya with Nripvallabha Ghrita along with Pathyadi Ghana Vati orally: 1. Nripvallabha ghrita Dose ââ?¬â?? 6 drops per nostril Mode of administration ââ?¬â?? nasal route Duration - Ma

Sponsors

National Institute of Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients willing to participate in this trial through written informed consent 2. Patients presenting with symptoms of Ardhavabhedaka (migraine), described as per Ayurveda and modern science.

Exclusion criteria

Exclusion criteria: 1. Secondary headaches caused by meningitis, tumors, encephalitis, head and neck trauma, trigeminal neuralgia, cervical spondylitis, refractive errors, sinusitis and other disorders of cranium, neck, eyes, ears, nose, sinuses, teeth etc. 2. Patients with complicated Migraine like status migrainosus, hemiplegic migraine and having any chronic debilitating disease with other neurological pathology. 3. Pregnant and lactating women. 4. Patients suffering from any other major systemic disorders e.g. tuberculosis, cancer, heart disease etc. 5. Patients unfit for Jalaukavacharna such as patients with hemorrhagic diseases (e.g. hemophilia), anaemia, hypotension, severe allergic diathesis and on anticoagulant treatment.

Design outcomes

Primary

MeasureTime frame
Reduction in intensity and frequency of headacheTimepoint: 3 months

Secondary

MeasureTime frame
Any adverse event reported voluntarily,observed or enquired.Timepoint: 3 months

Countries

India

Contacts

Public ContactDr Shamsa Fiaz

National Institute of Ayurveda, Jaipur

shamsa_fiaz@yahoo.com8764009846

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026